English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Urokinase (UK) was administered to 55 cases, of possibly occlusive cerebrovascular accidents and its clinical effects were analyzed. The indication was considered by the elapsing time from the onset, the gravity of clinical signs, the localization and size of brain damage, the angiographical feature and the supposed pathohistological changes in brain. UK administration was controlled mainly by PT, PTT, fibrinogen-, FDP-content, ELT, platelet count and its functions as the monitoring parameters. Average doses of UK for adults, 30,000 IU twice daily, were continued for the first week, and then decreased by half every two or three days. The thrombolytic treatment was maintained for two to three weeks. Administration of Warfarrin or dextran sulfate was started several days before the discontinuation of UK therapy and continued for some weeks.  Depending on the response of the patients to this therapy, they were divided into five classes;  a) clinical improvement with visible resolution of thrombi proved by angiography or computerized tomography (14 cases),  b) clinical improvement without visible agniographic findings (35 cases),  c) no improvement in clinical and laboratory findings (3 cases),  d) clinical improvement with worsening of partial clinical signs (3 cases), and  e) clinical exacerbation without any effect (no case).

Evaluation of Urokinase Therapy for Cerebrovascular Occlusive Diseases